文献速递冠心病外科

单支与多支动脉移植临床结局的随机比较:ROMA试验的原理与研究方案

Randomized comparison of the clinical outcome of single versus multiple arterial grafts: the ROMA trial-rationale and study protocol.
PubMed 文献 · Eur J Cardiothorac Surg · 2017-01-01

ROMA试验假设在首次孤立非急诊冠状动脉旁路移植术中,使用2支或以上动脉移植相比单支动脉移植可减少全因死亡、卒中、出院后心肌梗死和/或再次血运重建的复合终点。该试验为前瞻性、非盲、随机事件驱动多中心研究,至少纳入4300例患者,随机分配至单支动脉移植或多支动脉移植组。

要点

  • 主要终点为全因死亡、卒中、出院后心梗和/或再次血运重建的复合终点。
  • 次要终点为全因死亡率,主要安全终点为全因死亡、卒中和心梗的复合终点。
  • 样本量设定为4300例患者,主要分析采用意向性治疗原则和Cox回归模型。

核心结论

  • 在首次孤立非急诊冠状动脉旁路移植术患者中,使用2支或以上动脉移植相比单支动脉移植可能降低全因死亡、卒中、出院后心肌梗死和/或再次血运重建的复合终点风险。
  • 使用2支或以上动脉移植相比单支动脉移植可能改善生存。

研究设计与样本

  • ROMA试验为前瞻性、非盲、随机事件驱动多中心试验,至少纳入4300例患者。
  • 患者年龄小于70岁,患有左主干和/或多支血管病变,按1:1随机分配至单支动脉移植组或多支动脉移植组。
  • 随机化采用置换区组设计,按中心和第二支动脉移植类型分层。

关键数值与推荐

  • 主要终点为全因死亡、任何卒中、出院后心肌梗死和/或再次血运重建的复合终点。
  • 次要终点为全因死亡率。
  • 主要安全终点为全因死亡、任何卒中和任何心肌梗死的复合终点。
  • 检测主要终点20%相对降低,在90%把握度和5%α水平下,需845个事件(和3650例患者)。
  • 检测次要终点20%相对降低,在80%把握度和5%α水平下,需631个事件(和3650例患者)。

临床怎么用

  • 所有患者的一支内乳动脉吻合至左前降支冠状动脉。
  • 单支动脉移植组中,非左前降支靶血管使用大隐静脉桥。
  • 多支动脉移植组中,侧壁主要靶血管使用桡动脉或第二支内乳动脉移植,额外移植可选用大隐静脉或补充动脉导管。

局限性

  • 试验为非盲设计。
  • 主要分析基于意向性治疗原则,若观察到非比例风险将探索Cox比例风险回归的替代方法。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

SUMMARY: The primary hypothesis of the ROMA trial is that in patients undergoing primary isolated non-emergent coronary artery bypass grafting, the use of 2 or more arterial grafts compared with a single arterial graft (SAG) is associated with a reduction in the composite outcome of death from any cause, any stroke, post-discharge myocardial infarction and/or repeat revascularization. UNLABELLED: The secondary hypothesis is that in these patients, the use of 2 or more arterial grafts compared with a SAG is associated with improved survival. The ROMA trial is a prospective, unblinded, randomized event-driven multicentre trial comprising at least 4300 subjects. Patients younger than 70 years with left main and/or multivessel disease will be randomized to a SAG or multiple arterial grafts to the left coronary system in a 1:1 fashion. Permuted block randomization stratified by the centre and the type of second arterial graft will be used. The primary outcome will be a composite of death from any cause, any stroke, post-discharge myocardial infarction and/or repeat revascularization. The secondary outcome will be all-cause mortality. The primary safety outcome will be a composite of death from any cause, any stroke and any myocardial infarction. In all patients, 1 internal thoracic artery will be anastomosed to the left anterior descending coronary artery. For patients randomized to the SAG group, saphenous vein grafts will be used for all non-left anterior descending target vessels. For patients randomized to the multiple arterial graft group, the main target vessel of the lateral wall will be grafted with either a radial artery or a second internal thoracic artery. Additional grafts for the multiple arterial graft group can be saphenous veins or supplemental arterial conduits. To detect a 20% relative reduction in the primary outcome, with 90% power at 5% alpha and assuming a time-to-event analysis, the sample size must include 845 events (and 3650 patients). To detect a 20% relative reduction in the secondary outcome, with 80% power at 5% alpha, the sample size must include 631 events (and 3650 patients). To be conservative, the sample size will be set at 4300 patients. The primary outcome will be tested according to the intention-to-treat principle. The primary analysis will be a Cox proportional hazards regression model, with the treatment arm included as a covariate. If non-proportional hazards are observed, alternatives to Cox proportional hazards regression will be explored.

来源:Eur J Cardiothorac Surg,查看原文。版权归原作者所有。

引用

  1. Gaudino M, Alexander JH, Bakaeen FG, et al. Randomized comparison of the clinical outcome of single versus multiple arterial grafts: the ROMA trial-rationale and study protocol. Eur J Cardiothorac Surg. 2017. PMID: 29059371. doi:10.1093/ejcts/ezx358

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。